{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T23:18:04Z","timestamp":1648941484902},"reference-count":15,"publisher":"FapUNIFESP (SciELO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1590\/s0100-879x2010007500026","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T10:34:02Z","timestamp":1270722842000},"page":"580-584","source":"Crossref","is-referenced-by-count":0,"title":["Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia"],"prefix":"10.1590","volume":"43","author":[{"given":"G.A.P.","family":"Oliveira","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil; Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.S.","family":"Costa","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Freitas","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.F.","family":"Dutra","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.","family":"Maia","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Guerra","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca,  Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Borojevic","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.B.","family":"Otazu","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil; Abu Dhabi,  United Arab Emirates (UAE)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Silva","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/1097-0142(19911015)68:8<1678::AID-CNCR2820680803>3.0.CO;2-J","article-title":"Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia","volume":"68","author":"Dow LW","year":"1991","journal-title":"Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00043426-200201000-00006","article-title":"Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"24","author":"Millot F","year":"2002","journal-title":"J Pediatr Hematol Oncol","ISSN":"http:\/\/id.crossref.org\/issn\/1077-4114","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/pbc.20062","article-title":"Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?","volume":"43","author":"Pulsipher MA","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"ref4","first-page":"1659","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4","volume":"103","author":"Lahaye T","year":"2005","journal-title":"5-year follow-up. Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford S","year":"2003","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s Oncology Group phase 1 study","volume":"104","author":"Champagne MA","year":"2004","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.leu.2404051","article-title":"Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation","volume":"20","author":"Millot F","year":"2006","journal-title":"Leukemia","ISSN":"http:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/sj.leu.2402963","article-title":"Patterns of BCR\/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR\/ABL+ leukemias: incidence and underlying genetic abnormalities","volume":"17","author":"Primo D","year":"2003","journal-title":"Leukemia","ISSN":"http:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/10428190009057647","article-title":"Detection of BCR-ABL transcripts by multiplex and nested PCR in different haematological disorders","volume":"37","author":"Otaz\u00fa IB","year":"2000","journal-title":"Leuk Lymphoma","ISSN":"http:\/\/id.crossref.org\/issn\/1042-8194","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0145-2126(01)00109-6","article-title":"Estimations of BCR-ABL\/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion","volume":"26","author":"Otaz\u00fa IB","year":"2002","journal-title":"Leuk Res","ISSN":"http:\/\/id.crossref.org\/issn\/0145-2126","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus A","year":"2008","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/sj.leu.2403033","article-title":"Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha: Low levels of residual disease are associated with continuous remission","volume":"17","author":"Paschka P","year":"2003","journal-title":"Leukemia","ISSN":"http:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(86)90450-2","article-title":"Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene","volume":"47","author":"Shtivelman E","year":"1986","journal-title":"Cell","ISSN":"http:\/\/id.crossref.org\/issn\/0092-8674","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne C","year":"2002","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad JS","year":"2006","journal-title":"Leukemia","ISSN":"http:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjmbr\/v43n6\/107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T16:04:22Z","timestamp":1495814662000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2010000600009&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0100-879X2010000600009"],"URL":"https:\/\/doi.org\/10.1590\/s0100-879x2010007500026","relation":{},"ISSN":["0100-879X"],"issn-type":[{"value":"0100-879X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}